Clinical Trial: NCT04895358
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 3| Lead Sponsor: | Merck Sharp & Dohme LLC |
| Information Provided By: | Merck Sharp & Dohme LLC |
| Last Update Posted: | 2026-07-22 |
Study Overview
Brief Summary
The safety and efficacy of pembrolizumab plus the investigator's choice of chemotherapy will be assessed compared to placebo plus the investigator's choice of chemotherapy in the treatment of chemotherapy-candidate hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally recurrent inoperable or metastatic breast cancer.
The primary hypotheses are that the combination of pembrolizumab and chemotherapy is superior to placebo and chemotherapy in regards to Progression-Free Survival (PFS) in participants with programmed cell death-ligand 1 (PD-L1) combined positive score (CPS) ≥1.
Prior to protocol amendment 7, participants who discontinued pembrolizumab/placebo with SD or better and subsequently experienced disease progression may have been eligible for up to 17 additional administrations of pembrolizumab if, upon unblinding, they were found to have received pembrolizumab, at the same dose and schedule used for the initial treatment period.
Official Title
Conditions
Intervention / Treatment
- Biological: pembrolizumab
- Drug: paclitaxel
- Drug: nab-paclitaxel
- Drug: liposomal doxorubicin
- Drug: capecitabine
- Drug: normal saline
- Drug: dextrose
Other Study ID Numbers
- 3475-B49
- MK-3475-B49
- KEYNOTE-B49
- 2023-506752-24-00
- U1111-1294-3354
- jRCT2051210049
- PHRR210721-003751
- 2020-005407-38
- 2023
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Estimated)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | Merck Sharp & Dohme LLC |
| Information Provided By: | Merck Sharp & Dohme LLC |
| Last Update Posted: | 2026-07-22 |
Study Overview
Brief Summary
The safety and efficacy of pembrolizumab plus the investigator's choice of chemotherapy will be assessed compared to placebo plus the investigator's choice of chemotherapy in the treatment of chemotherapy-candidate hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally recurrent inoperable or metastatic breast cancer.
The primary hypotheses are that the combination of pembrolizumab and chemotherapy is superior to placebo and chemotherapy in regards to Progression-Free Survival (PFS) in participants with programmed cell death-ligand 1 (PD-L1) combined positive score (CPS) ≥1.
Prior to protocol amendment 7, participants who discontinued pembrolizumab/placebo with SD or better and subsequently experienced disease progression may have been eligible for up to 17 additional administrations of pembrolizumab if, upon unblinding, they were found to have received pembrolizumab, at the same dose and schedule used for the initial treatment period.
Official Title
Conditions
Intervention / Treatment
- Biological: pembrolizumab
- Drug: paclitaxel
- Drug: nab-paclitaxel
- Drug: liposomal doxorubicin
- Drug: capecitabine
- Drug: normal saline
- Drug: dextrose
Other Study ID Numbers
- 3475-B49
- MK-3475-B49
- KEYNOTE-B49
- 2023-506752-24-00
- U1111-1294-3354
- jRCT2051210049
- PHRR210721-003751
- 2020-005407-38
- 2023